ImmunityBio, Inc. (IBRX): Revenue
$113.29M
Year ended 2025-12-31
$165.79M
Trailing 12 months to 2026-06-30
n/m
3-year compound annual growth
n/m
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $113.29M | +668.3% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $14.74M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $622.0K | +159.2% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $240.0K | -74.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $934.0K | +54.4% | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | $605.0K | -72.5% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $2.20M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $47.0K | +4.4% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $45.0K | +2.3% | 2020-03-25, From 2017-01-01 |
| 2016-12-31 | $44.0K | -81.4% | 2019-03-13, From 2016-01-01 |
| 2015-12-31 | $236.0K | -63.2% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $641.0K | +6.8% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $600.0K | n/a | 2016-03-30, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $113.29M | +668.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $114.20M | +10.4% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $109.16M | n/m |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $120.77M | -6.3% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $123.67M | +63.5% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $102.48M | +65.2% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $139.74M | +120.0% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $85.21M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $81.39M | +144.6% |
Compare IBRX, AGEN, IPSC, ATRA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗